Invivyd (IVVD) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed Invivyd (IVVD) over the past year, gaining 62.2% versus a loss of 57.3%. Over five years, WHWK leads with a -87.1% price change compared with -97.8% for IVVD. Invivyd is the larger company by market cap ($212.6 million vs $200.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | WHWK |
|---|---|---|
| Share price | $0.7212 | $3.52 |
| Market cap | $212.58M | $200.67M |
| 1-day change | +2.97% | +1.44% |
| YTD return | -71.64% | +45.45% |
| 1-year return | -57.29% | +62.21% |
| 5-year return | -97.84% | -87.06% |
| EPS (TTM) | $-0.33 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $5.50 |
| 52-week low | $0.528 | $1.87 |
| Distance from 52-week high | -76.51% | -35.94% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +1286.58% | +119.03% |
| Average volume | 4.90M | 367.72K |
| Shares outstanding | 294.76M | 57.01M |
| Employees | 122 | 32 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed IVVD by 119.5 percentage points over the past year.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
IVVD vs WHWK FAQ
Which is bigger, Invivyd or Whitehawk Therapeutics?
Invivyd (IVVD) is larger, with a market capitalization of $212.58M compared with $200.67M for Whitehawk Therapeutics (WHWK).
Which stock has performed better over the past year, IVVD or WHWK?
WHWK returned +62.21% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Whitehawk Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Invivyd and Biotechnology: Pharmaceutical Preparations for Whitehawk Therapeutics.